GILEAD SCIENCES, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 29 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-08-26: Reporting owner WELTERS ANTHONY; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-26: Reporting owner WELTERS ANTHONY; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-20: Reporting owner Bluestone Jeffrey; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-20: Reporting owner Bluestone Jeffrey; Form 4; Security Non-qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
GILD insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | WELTERS ANTHONY Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,718 0 owned after | $60.67 exercise price | $148.09 | 2026-08-27 |
| 2026-08-26 | WELTERS ANTHONY Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,282 5,569 owned after | $61.35 exercise price | $148.09 | 2026-08-27 |
| 2026-08-20 | Bluestone Jeffrey Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,665 0 owned after | $67.45 exercise price | $143.44 | 2026-08-21 |
| 2026-08-20 | Bluestone Jeffrey Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −335 11,395 owned after | $61.35 exercise price | $143.44 | 2026-08-21 |
| 2026-08-17 | Mercier Johanna Officer (Chief Comm & Corp Aff Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,110 0 owned after | $66.64 exercise price | $138.92 | 2026-08-18 |
| 2026-08-17 | Mercier Johanna Officer (Chief Comm & Corp Aff Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,890 69,960 owned after | $72.34 exercise price | $138.92 | 2026-08-18 |
| 2026-05-15 | Mercier Johanna Officer (Chief Comm & Corp Aff Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 23,110 owned after | $66.64 exercise price | $129.58 | 2026-05-18 |
| 2026-04-30 | Bluestone Jeffrey Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | BARTON JACQUELINE K Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | Horning Sandra Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | LOVE TED W Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | Rodriguez Javier Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | WELTERS ANTHONY Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | MANWANI HARISH Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-04-30 | Kramer Kelly A. Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,884 4,884 owned after | $130.84 exercise price | $130.84 | 2026-05-04 |
| 2026-03-10 | Dickinson Andrew D Officer (Chief Financial Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,880 35,880 owned after | $148.56 exercise price | $148.56 | 2026-03-12 |
| 2026-03-10 | Mercier Johanna Officer (Chief Comm & Corp Aff Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,880 35,880 owned after | $148.56 exercise price | $148.56 | 2026-03-12 |
| 2026-03-10 | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,885 18,885 owned after | $148.56 exercise price | $148.56 | 2026-03-12 |
| 2026-03-10 | Burkhart Erin Officer (SVP, Controllership) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,455 5,455 owned after | $148.56 exercise price | $148.56 | 2026-03-12 |
| 2026-03-10 | O'Day Daniel Patrick Director, Officer (Chairman & CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +122,755 122,755 owned after | $148.56 exercise price | $148.56 | 2026-03-12 |
| 2026-03-10 | Berger Dietmar Officer (Chief Medical Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,475 31,475 owned after | $148.56 exercise price | $148.56 | 2026-03-12 |
| 2026-02-17 | Mercier Johanna Officer (Chief Comm & Corp Aff Officer) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 48,110 owned after | $66.64 exercise price | $155.27 | 2026-02-18 |
| 2026-02-12 holding as of filing | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $57.92 exercise price | 2026-02-12 | ||
| 2026-02-12 holding as of filing | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $79.50 exercise price | 2026-02-12 | ||
| 2026-02-12 holding as of filing | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $75.12 exercise price | 2026-02-12 | ||
| 2026-02-12 holding as of filing | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | 3 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | Holding | $117.21 exercise price | 2026-02-12 | ||
| 2026-02-05 | O'Day Daniel Patrick Director, Officer (Chairman & CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −115,640 0 owned after | $66.01 exercise price | $149.37 | 2026-02-06 |
| 2026-01-23 | O'Day Daniel Patrick Director, Officer (Chairman & CEO) | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −115,640 115,640 owned after | $66.01 exercise price | $135.93 | 2026-01-26 |
| 2026-01-20 | Bluestone Jeffrey Director | 4 | Non-qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 4,665 owned after | $67.45 exercise price | $124.14 | 2026-01-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |